Archived ASX Releases
Also in this section
2015 ASX Releases
2014 ASX Releases
2013 ASX Releases
2012 ASX Releases
2011 ASX Releases
2010 ASX Releases
2009 ASX Releases
2008 ASX Releases
CHANGES TO CSL SENIOR EXECUTIVE GROUP
CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, announced today a number of changes in its organisation structure and its senior executive group, within the context that Dr Brian McNamee would be continuing as CEO and Managing Director for at least a further three to four years.
Full-year results for 2008/09
CSL Limited today announced a profit after tax of $1.15 billion for the twelve months ended 30 June 2009, up 63% when compared to the twelve months ended 30 June 2008.
Recording of Analyst Briefing
Analyst Briefing with CSL Managing Director and Chief Executive Officer, Dr Brian McNamee. This was recorded on June 9th 2009 following the announcement that CSL and Talecris Biotherapeutics have agreed to terminate the merger agreement.
CSL announces on-market share buyback
CSL Limited (ASX:CSL) today announced its intention to conduct an on-market share buyback of up to 54,863,000 shares1
. This represents approximately 9% of the company’s current shares on issue. At an assumed price per share of approximately A$29 (being CSL's last closing price on Friday 5 June), this would represent a total buy back consideration of up to A$1.59 billion.
CSL Limited responds to FTC announcement
CSL Limited (ASX: CSL) today was informed that the US Federal Trade Commission (“FTC”) will file a complaint in the US Federal District Court to challenge CSL’s proposed acquisition of Talecris Biotherapeutics.
CSL Half-year Results Announcement for 2008/09
CSL Limited today reported a profit after tax of $502 million
for the six months ended 31 December 2008, up 44% when compared to the six months
ended 31 December 2007. This included a foreign currency benefit of $26 million and a
number of favourable non operational items totalling $44 million in net profit after tax
which also boosted the result. Adjusting for currency and the items above, underlying profit
growth was 24%.